Solta Medical Appoints Lisa Parr as Vice President of Regulatory Affairs and Clinical Affairs

HAYWARD, Calif., Nov. 15, 2012 /PRNewswire/ -- Solta Medical, Inc. (NASDAQ: SLTM), a global leader in the medical aesthetics market, today announced the appointment of Dr. Lisa Parr to the position of Vice President of Regulatory Affairs and Clinical Affairs.

Dr. Parr brings nearly 25 years of senior management experience successfully leading clinical and regulatory initiatives for medical device, pharmaceutical, and consumer product companies. Dr. Parr was most recently the Vice President of Clinical, Regulatory, and Quality Affairs at Tria Beauty where she secured a number of regulatory clearances for light-based aesthetic and therapeutic devices for at-home use.

"I am delighted that Lisa is joining our management team. She has established a reputation among her peers for collaborative team building and disciplined execution," said Stephen J. Fanning, Chairman, President & CEO. "Her extensive and diverse expertise in regulatory affairs and clinical development will be a valuable asset in opening new markets for Solta products and advancing our new product pipeline."

About Solta Medical, Inc.
Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers six aesthetic energy devices to address a range of issues, including skin resurfacing and rejuvenation with Fraxel® and Clear + Brilliant(TM), body contouring and skin tightening with Liposonix® and Thermage® and acne reduction with Isolaz® and CLARO(TM). As the innovator and leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Using similar fractional laser technology, Clear + Brilliant is a unique, cost-effective treatment to prevent and improve the early signs of photoaging. For body contouring, Liposonix is a non-surgical treatment to reduce waist circumference with advanced high-intensity focused ultrasound (HIFU) technology to permanently destroy targeted fat beneath the skin. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. Isolaz was the first laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. CLARO is a personal care acne system that is the first FDA cleared over-the-counter IPL device that uses a powerful combination of both heat and light to clear skin quickly and naturally. More than two million procedures have been performed with Solta Medical's portfolio of products around the world. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.

Web Site: http://www.Solta.com 

SOURCE Solta Medical, Inc.

Copyright 2012 PR Newswire

Solta Medical, (MM) (NASDAQ:SLTM)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Solta Medical, (MM) Charts.
Solta Medical, (MM) (NASDAQ:SLTM)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Solta Medical, (MM) Charts.